Skip to content
Open access

Association of CT-defined sarcopenia with survival and therapeutic response in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis

Oct 2026 · BMC Gastroenterology · 0 citations

TL;DR

CT-defined sarcopenia was significantly associated with poorer survival and therapeutic response among HCC patients receiving TACE and patients with sarcopenia were more likely to experience worse survival and therapeutic response.

Abstract

The prognostic impact of CT-defined sarcopenia in hepatocellular carcinoma (HCC) patients who received the transarterial chemoembolization (TACE) remains unclear. This study aimed to clarify the impact of CT-defined sarcopenia on survival and therapeutic response in HCC patients receiving TACE. PubMed, Web of Science and CNKI databases were searched up to April 18, 2026. Primary endpoints included the overall survival (OS) and progression-free survival (PFS) and secondary endpoints were objective response rate (ORR) and disease control rate (DCR). Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were combined to evaluate the impact of CT-defined sarcopenia on primary and secondary endpoints. Sixteen studies with 3359 cases were included. As for primary outcomes, the presence of CT-defined sarcopenia was significantly related to poorer OS (HR = 1.79, 95% CI: 1.47–2.18, P < 0.001) and PFS (HR = 1.65, 95% CI: 1.42–1.92, P < 0.001). Besides, subgroup analysis stratified by the country, sample size, combination of other therapies, source of HR and defining method of sarcopenia manifested similar findings. As for secondary outcomes, CT-defined sarcopenia was also associated with decreased ORR (OR = 0.55, 95% CI: 0.38–0.81, P = 0.002) and DCR (OR = 0.50, 95% CI: 0.37–0.67, P < 0.001). CT-defined sarcopenia was significantly associated with poorer survival and therapeutic response among HCC patients receiving TACE and patients with sarcopenia were more likely to experience worse survival and therapeutic response.

Read PDF

Similar papers

Open access Oct 2026

CT-defined sarcopenia and outcomes in HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors

Sarcopenia is increasingly recognized as a potential prognostic factor in patients with cancer, but its clinical significance in HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors remains uncertain. This study investigated the association between CT-defined sarcopenia and clinical outcomes in this po...

Zeynep Alaca Topçu, Zehra Sucuoğlu İşleyen, Ismail Yurtsever et al. · 0 citations
Open access Sep 2026

Prognostic value of systemic inflammatory markers in patients with resectable hepatocellular carcinoma: a meta-analysis

Preoperative systemic inflammatory markers are inexpensive candidate prognostic factors after hepatocellular carcinoma (HCC) resection, but heterogeneous populations, endpoints, effect measures, and cutoff selection may limit interpretation. Full texts were re-screened using a strict definition of primary HCC treated b...

Jian-Guo Chen, Hong-Yang Han, Guang-Wei Yang et al. · 0 citations
Open access Nov 2026

Survival benefits of complete ablation in patients with BCLC stage B hepatocellular carcinoma receiving transarterial chemoembolization and systemic therapy

In patients with BCLC stage B HCC receiving TACE combined with systemic therapy, complete ablation was associated with improved survival and a model to identify patients most likely to benefit from the treatment was developed.

Y. Xiong, Chen Wang, Ting-Ting Mei et al. · 0 citations
Sep 2026

Prediction of the Efficacy of PA-TACE in Patients with Clearly Defined Hepatocellular Carcinoma by Imaging Combined with Serology: A Retrospective Cohort Study with a Two-Center Follow-Up of up to 12 Years.

The suggested dual-center nomogram shows excellent practical relevance in assessing the effectiveness of PA-TACE and improving postoperative care techniques, and integrates CT radiomics and serological markers, with overall survival as the major outcome.

Jin-Yi Liu, Qiang Xu, Qian Song et al. · 0 citations
Open access Oct 2026

Efficacy and safety of sintilimab plus bevacizumab with or without transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score-matched retrospective cohort study.

Background To compare the efficacy and safety of transarterial chemoembolization (TACE) plus sintilimab and bevacizumab (triple therapy) versus sintilimab and bevacizumab alone (dual therapy) in unresectable hepatocellular carcinoma (uHCC). Methods This single-center retrospective cohort study enrolled consecutive pa...

Zi-Zhuo Wang, Bai-Lu Wu, Chun-Shu Wu et al. · 0 citations
Open access Oct 2026

Retrospective observational study of transcatheter arterial chemoembolization (TACE) combined with PD-1 inhibitor and tyrosine kinase inhibitor (TKI) in advanced hepatocellular carcinoma

Transcatheter arterial chemoembolization (TACE) induces tumor necrosis and antigen release, but the resulting hypoxic microenvironment upregulates programmed death-ligand 1and vascular endothelial growth factor, providing a biological rationale for adding a programmed death-1 (PD-1) inhibitor and a TKI. The study aims...

Guo-Hui Xu, Jian-Long Zhang, Xiao-Jun Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.